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Abstract
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by pathological
deposition of misfolded self-protein amyloid beta (Aβ) which in kind facilitates tau aggregation and neurodegeneration. Neuroinflammation is accepted as a key disease driver caused by innate microglia activation. Recently, adaptive
immune alterations have been uncovered that begin early and persist throughout the disease. How these occur
and whether they can be harnessed to halt disease progress is unclear. We propose that self-antigens would induct
autoreactive effector T cells (Teffs) that drive pro-inflammatory and neurodestructive immunity leading to cognitive
impairments. Here, we investigated the role of effector immunity and how it could affect cellular-level disease pathobiology in an AD animal model.
Methods: In this report, we developed and characterized cloned lines of amyloid beta (Aβ) reactive type 1 T helper
(Th1) and type 17 Th (Th17) cells to study their role in AD pathogenesis. The cellular phenotype and antigen-specificity of Aβ-specific Th1 and Th17 clones were confirmed using flow cytometry, immunoblot staining and Aβ T cell
epitope loaded haplotype-matched major histocompatibility complex II IAb (MHCII-IAb–KLVFFAEDVGSNKGA) tetramer
binding. Aβ-Th1 and Aβ-Th17 clones were adoptively transferred into APP/PS1 double-transgenic mice expressing
chimeric mouse/human amyloid precursor protein and mutant human presenilin 1, and the mice were assessed for
memory impairments. Finally, blood, spleen, lymph nodes and brain were harvested for immunological, biochemical,
and histological analyses.
Results: The propagated Aβ-Th1 and Aβ-Th17 clones were confirmed stable and long-lived. Treatment of APP/PS1
mice with Aβ reactive Teffs accelerated memory impairment and systemic inflammation, increased amyloid burden,
elevated microglia activation, and exacerbated neuroinflammation. Both Th1 and Th17 Aβ-reactive Teffs progressed
AD pathology by downregulating anti-inflammatory and immunosuppressive regulatory T cells (Tregs) as recorded in
the periphery and within the central nervous system.
Conclusions: These results underscore an important pathological role for CD4+ Teffs in AD progression. We posit
that aberrant disease-associated effector T cell immune responses can be controlled. One solution is by Aβ reactive
Tregs.
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Background
Alzheimer’s disease (AD) is the most common form of
age-associated dementia and has become the sixth leading cause of death in the United States [1, 2]. AD is characterized by the presence of misfolded self-proteins.
Those self-proteins include amyloid beta (Aβ) and hyperphosphorylated tau present within the brain and the systemic circulation [3, 4]. Aβ and tau aggregate and deposit
among brain tissues as senile or amyloid plaques and
neurofibrillary tangles. In addition, neuroinflammation
persists and has been identified as a key disease-driving
factor [2, 5]. Both innate and adaptive immunity play disease-propagating roles [2, 6, 7]. Central nervous system
(CNS) innate microglial cells and astrocytes are activated
by the disease proteins and contribute to neuronal injuries by producing inflammatory and neurotoxic factors.
These increase aberrant amyloid precursor protein (APP)
cleavage, Aβ production, and tau phosphorylation [8, 9].
The role of adaptive immune T cells in AD pathogenesis
is under-reported and less well understood. We posit

that understanding disease-linked adaptive immunity
will permit the harnessing of peripheral immune T cell
responses to facilitate AD therapeutic management.
The peripheral adaptive immune system, comprised
of cytokine secreting T cells, monocytes, and B lymphocytes, is activated by modified self-peptide fragments,
such as Aβ and tau. These are engulfed and presented
by antigen presenting cells (APCs) [2, 10]. T cell subsets
contribute either effector or regulatory functions that
are maintained during homeostatic conditions to maintain immunological tolerance. However, in pathological
states, effector T cell (Teff ) subsets react against misfolded and disease-specific self-proteins that can break
immune tolerance and expand self-reactive T cells [2, 11,
12]. Clonal expansion of CD8+ Teffs in both the periphery and CNS has been shown in AD patients [13]. Similarly, elevated CD4+ Teffs are reported in AD patients
with mild cognitive impairment [14–16]. Additionally, CD4+ Teff subsets reactive against AD-associated
pathological proteins that included Aβ-reactive type 1
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T helper (Th1), type 2 Th (Th2), and type 17 Th (Th17)
cells were studied in mixed microglia–astroglia cultures.
These studies demonstrated that glial pro-inflammatory
responses are driven by Th1 and Th17 and regulated by
Th2 cells [17]. Among Aβ responsive Th1, Th2, and Th17
cells, only interferon gamma (IFNγ)-secreting Th1 cells
accelerate disease in double transgenic mice expressing
chimeric mouse/human amyloid precursor protein and
mutant human presenilin 1 (APP/PS1). Disease can be
corrected by passive transfer of anti-IFNγ antibodies [18].
In contrast, protective effects of intracerebroventricularly
injected Aβ-specific Th1 cells in 5XFAD (C57BL6) mice
facilitate enhancement of microglial major histocompatibility complex class II (MHCII) and increased phagocytic
activities [19, 20]. Overall, the role played by CD4+ Teffs
in AD pathogenesis remains incompletely understood. In
this report, we investigated the role of Teffs in AD-associated brain pathologies by developing Aβ-specific CD4+
Th1 and Th17 Teff clonal cell lines, used to study the
role of Aβ-specific Teffs in AD progression. The unique
cytokine signature, transcription factor expression, and
MHCII-IAb-Aβ tetramer staining affirmed a distinctive
cellular phenotype and antigen specificity. Aβ-reactive
Th1 and Th17 Teffs, adoptively transferred into APP/PS1
mice demonstrated accelerated behavioral and pathological disease, thus supporting a role as disease perpetrators. This suggests an evolving role for CD4+ Teffs in AD
progression with opportunities for therapeutic interventions by immune modulation.

Results
Aβ-Th1 and Aβ-Th17 cell phenotypes are stable

Previous works developed antigen-specific T cells from
Aβ1–42 immunization of non-transgenic (non-Tg) mice.
However, those cells were polarized for a short period
prior to adoptive transfer with uncertain phenotypes [18,
19]. Here, we developed stable Aβ-specific Teff clones
that were maintained in culture for more than 6 months
and retained antigen specificity and phenotype. Flow
cytometric analysis for intracellular cytokines revealed
that activated Aβ-Th1 cells expressed pro-inflammatory
cytokines, interferon gamma (IFNγ) (44.1%) and tumor
necrosis factor alpha (TNFα) (52.3%), and expressed
nuclear transcription factor T-box expressed in T cells
(Tbet) (85.6%). Aβ-Th17 cells preferentially expressed
interleukin 17 (IL17) (43.7%) and transcription factor
RAR-related orphan receptor gamma (RORγ) (92.7%)
(Fig. 1a). To further confirm the cellular phenotype of
Aβ-Teffs, extracellular cytokine release was assessed by
the immunoblot staining, which showed that Aβ-Th1
cells selectively secreted IFNγ, while Aβ-Th17 cells
secreted higher levels of IL17 (Fig. 1b). Both Aβ-Th1 and
Aβ-Th17 cells secreted TNFα after activation, although
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higher expression was observed in Aβ-Th1 cells. Aβ-Th1
and Aβ-Th17 cells also upregulated chemokines CCL3
(MIP-1α) and CCL4 (MIP-1β), but expression was 35%
higher in Aβ-Th1 cells compared to Aβ-Th17 cells. CCL3
and CCL4 have been implicated in different inflammatory conditions and are produced in substantial quantities by the Th1 type lymphocytes [21], further supporting
the cellular phenotype of Aβ-Teffs. The unique T cell
receptor (TCR) recognizes cognate antigen when presented by the major histocompatibility complex type I or
type II (MCH-I or -II) molecules of antigen presenting
cells (APCs) [2, 10]. To determine the antigen specificity
of Teff clones, Aβ-Th1 and Aβ-Th17 cells were incubated
with fluorescently labeled MHCII-IAb–KLVFFAEDVGSNKGA tetramer. The 3-month Aβ-Th1 and Aβ-Th17
clones showed binding with MHC–peptide tetramer in
a dose-dependent manner, confirming their Aβ specificity (Additional file 1: Fig. S1b). Prolonged maintenance
of stable Teff clones (6 months) maintained their cognate
antigen recognition seen through dose-dependent Aβ–
Teff–MHC–peptide binding in Fig. 2a comparable to the
3-month clones (Additional file 1: Fig. S1b).
To provide greater insight in parent Th1 clone interaction with Aβ peptide bound to MHCII-IAb, TCRα and
TCRβ chain sequences were identified, and molecular
modeling studies were performed with peptide–MHCII
(pMHC) complex (Fig. 2b). Molecular modeling of
full-length TCRα/β complex with Aβ1–42–MHCII–IAb
(pMHCII) complex was performed to determine exact
amino acid interactions between two complexes [22]. The
model was constructed with structural assessment, validation for various features, bond orientation, and overall
quality of model performed. pMHC complex consisted of
MHCII-IAbα (green chain), MHCII-IAbβ (cyan chain),
and Aβ peptide (blue chain) (Fig. 2b). TCR complex consisted of TCRα (yellow chain) and TCRβ (red chain). The
Ramachandran plot or the φ/ψ plot predicts the conformational stability of the models, the TCR–pMHC complex had a RC score of 98.35% for favored region and
0.44% for outliers suggested its good quality (Additional
file 1: Fig. S2a(i,ii)). MolProbity score and the QMEAN
score reflects overall quality of the model, herein they
were 0.66 and −3.60, respectively. The TCR–pMHC
complex was subjected to molecular dynamics (MD)
simulations and the final structure from the 100 ns MD
trajectory was analyzed for its root-mean-square deviation (RMSD) and root-mean-square fluctuations (RMSF)
for individual amino acid residues [23]. The RMSD during the MD simulation for whole complex gradually rose
by 5 Å from 2 to 7 Å during the initial 40 ns and then
converged to stabilize between 1.5 Å (5.5 to 7 Å) for rest
of the simulation (Additional file 1: Fig. S2a(iii)). The
RMSF during the simulation was observed between 1 to
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Fig. 1 Cellular phenotype of the Aβ-Th1 and Aβ-Th17 cells. a Flow cytometric analysis of intracellular cytokine and transcription factor expressed by
Aβ-Th1 and Aβ-Th17 cells that were maintained as clones for greater than 6 months. T cells were stimulated for 12 h with PMA and ionomycin in the
presence of brefeldin A. b Representative immunoblot and quantification for 42 different cytokines and chemokines extracellularly secreted from
Aβ-Th1 and Aβ-Th17 cells after stimulation with PMA and ionomycin

14 Å with most of the residues having RMSF between
1 to 3 Å (Additional file 1: Fig. S2a(iv)). The individual components of the complex were studied and the
RMSF for each component was analyzed. MHCα and
MHCβ are green and cyan colored ribbons, respectively
(Fig. 2b(i)), MHCα had RMSF of 3 Å for N-terminal Met1
and about 2 Å for C-terminal Glu73 (Additional file 1:
Fig. S3b(ii)), the residues belonging to the loop regions
(residues 40–45) had very high RMSF of about 8.5 Å.
The MHCβ had RMSF of 2.25 Å for N-terminal Met257
and about 4.5 Å for C-terminal Gln521 (Additional file 1:
Fig. S2b(iii)). Aβ peptide N-terminal residue Asp522 and
C-terminal residue Ala563 showed interactions with
MHC and TCR molecules (Fig. 2b(i)). Stabilized fluctuations and formation of multiple interactions between
peptide–MHC and pMHC–TCR are shown under the
surface diagram (Fig. 2c(i)). MHCα and MHCβ showed
multiple interactions with Aβ peptide; Ala563 of peptide interacted with Arg168 of MHCα chain and Arg322
of MHCβ chain to form donor–receptor pair leading
to hydrogen bonds formation (Fig. 2c(ii)). Aβ residue
Lys549 formed hydrogen bond interaction with backbone
of MHCα chain Arg168(O) (Fig. 2c(iii)) and with MHCα

chain Asp169(OD2) (Fig. 2c(iv)). TCR chains were analyzed for their RMSF; TCRα chain showed higher fluctuations of around 6 Å owing to terminal residues, but
TCRβ chain had lower RMSF between 1 and 3 Å for most
of the residues with the terminal residues showing about
10 Å, which was expected for the terminal helixes. The
Fab (fragment antigen binding) region showed lower
RMSF due to its complexation with pMHC molecule
(Additional file 1: Fig. S2b(i–iii)). pMHC molecule predominantly interacted with TCRβ chain and formed
multiple interactions; pMHC sidechain residues Glu543
and Ser547 formed hydrogen bonds with Tyr908, Asp953
and Gln952 of TCRβ (Fig. 2c(v)). pMHC residue His535
(NE2) formed hydrogen bond with Asn(O). His535 (O)
interacted with Tyr956 (OH) to form intermolecular
hydrogen bonding and due to stacking of the aromatic
rings Tyr956 and His535 also showed π–π interactions
(Fig. 2c(vi)); pMHC peptide residue Glu532 also interacted with TCRβ, Glu532(OE2)–Tyr961(OH) and Glu532
(OE1)–His886(NE2) (Fig. 2c(vii)). Higher fluctuations in
both TCRα and TCRβ chains were observed for the Fc
(fragment crystallizable) regions, which were attributed
to the helices that form C-terminals of TCRα and TCRβ
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Fig. 2 Antigen-specificity of the Aβ-Th1 and Aβ-Th17 cells a MHCII-IAb–KLVFFAEDVGSNKGA (Aβ T cell epitope) tetramer binding with Aβ-Th1 and
Aβ-Th17 cells after incubation. Control tetramer MHCII-IAb–PVSKMRMATPLLMQA was used for precise gating of Aβ T cell epitope recognizing CD4+
T cell population. b From Aβ-Th1 cells, antigen-recognizing variable regions of T cell receptor (TCR) alpha (α) and beta (β) chains were identified
using molecular cloning. Molecular modeling of full-length TCRα/β complex with Aβ1–42–MHCII-IAb (pMHC) complex; MHCII-IAbα chain (green),
MHCII-IAbβ chain (cyan) and peptide (blue); TCRα chain (yellow) and TCRβ chain (red). The interface of MHCII, peptide and TCR binding is shown
by encircled region. c (i) peptide surface at the interface of MHC and TCR. Peptide–MHC interactions; (ii) peptide Ala563 and Arg322 interaction
with MHCα Arg168 and MHCβ Arg322, respectively; (iii) peptide Lys549 interaction with MHCα Arg168(O); (iv) peptide Lys549 interaction with
MHCα Asp169(OD2); TCR–pMHC interactions- (v) pMHC Glu543 and Ser547 interaction with Tyr908, Asp953 and Gln952. (vi) pMHC His535 (NE2)
interaction with Asn(O), and His535 (O) interaction with Tyr956 (OH), π–π interactions between Tyr956 and His535; (vii) pMHC interaction with TCRβ,
Glu532(OE2)–Tyr961(OH) and Glu532 (OE1)–His886(NE2)

chains (Additional file 1: Fig. S2c(i–v)). The overall TCR–
pMHC model suggests interaction of Aβ peptide in the
region between residues Glu532 to Ala563 with MHC
molecule and TCR Fab region, with rest of the peptide
having very less to no interactions during the MD simulation of the complex.

Adoptive transfer of Aβ-Teffs accelerates memory
impairment in mice

To test the behavioral effects of Aβ-Teffs, 2 × 106 Aβ-Th1
or Aβ-Th17 cells were adoptively transferred to APP/
PS1 mice in 2 weekly doses and recipients were evaluated for spatial learning and memory in the radial arm
water maze (RAWM) test 2 weeks after second adoptive
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transfer (Fig. 3a). APP/PS1 mice showed signs of memory impairment evidenced by significant increases in
the number of errors in late retention trial T5 (p < 0.05,
block-1 and block-3) compared to non-Tg mice (Fig. 3b)
and were consistent with our previous reports [6]. Higher
number of memory errors were observed in APP/PS1
recipients that received either Aβ-Th1 or Aβ-Th17 cells
compared to non-Tg mice (Aβ-Th1 p < 0.01 in block-1
and p < 0.001 in block-3 while Aβ-Th17 p < 0.01 in block3). Additionally, APP/PS1 mice that received Aβ-Teffs
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exhibited 30% greater number of experimental errors
compared to untreated APP/PS1 mice, but were not significantly different. Overall, these results support the
notion that Aβ-Th1 and Aβ-Th17 Teffs increase memory
impairment development speed in APP/PS1 mice and is
linked to a pro-inflammatory phenotype under an amyloid enriched environment.
Alteration in brain glucose uptake and its subsequent
metabolism is a biomarker for memory impairment [24,
25], and has been used to confirm the effects of Aβ-Teffs

Fig. 3 Aβ-Th1 and Aβ-Th17 cells affect memory function in APP/PS1 mice. a Schematic presentation of the in vivo experimental procedure
performed in 4- to 5-month-old female APP/PS1 and age-matched non-Tg mice. n = 6 mice per group were used. b Radial arm water maze (RAWM)
test was performed with experimental mice 3 weeks after the first of two adoptive transfers with 1 × 106 Aβ-Th1 or Aβ-Th17 cells intravenously.
Errors of 9-day trials were divided into three blocks and averaged for the statistical analysis. Two-way ANOVA was used to determine significant
differences between experimental groups. *p < 0.05, **p < 0.01. c Fasting blood glucose concentrations were measured prior to the glucoCEST MRI.
d 2-deoxy-glucose (2DG) CEST MRI was performed 5 weeks after the Aβ-Th1 and Aβ-Th17 cells adoptive transfer. Representative MRI images with
hippocampal glucose signal are shown for different experimental mice which include baseline MRI scan followed by 2DG injection and thereafter
MRI scans every 10 min up to 1 h. n = 4 mice per group were analyzed. Glucose intensity in the hippocampus was calculated as %∆MTR at different
time points compared to the baseline. Area under the curve (AUC) for each mouse was calculated and averaged for statistical significance using
one-way ANOVA followed by Newman–Keuls post hoc test. Same line colors and symbols are used to show different groups in b and d
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on the memory functions of APP/PS1 mice. 18F-radiolabeled fluorodeoxyglucose (18F-FDG) positron emission
tomography (PET) imaging is commonly used for the
diagnosis of dementia stage in the AD patients [26, 27]
and in laboratory animal models [28, 29], whereas nonradiolabeled 2-deoxy glucose (2DG) chemical exchange
saturation transfer (CEST)-MRI has been shown to assess
the glucose uptake in AD animal models with better resolution [30]. 2DG can quickly enter the brain via the same
transporters for the D-glucose, where it is metabolized
into 2DG-6-phosphate (2DG6P), but minimally metabolized further. Due to low blood–brain barrier (BBB)
permeability, 2DG6P is trapped inside the brain that
allows assessment of glucose uptake by the CEST-MRI
approach as described earlier [31]. Prior to glucoCEST,
fasting blood glucose concentration was reduced in APP/
PS1 mice (11%) compared to non-Tg mice, whereas concentrations in APP/PS1/Aβ-Th1 and APP/PS1/Aβ-Th17
mice decreased by 27% and 23%, respectively (Fig. 3c).
Non-Tg mice showed highest 2DG uptake as glucoCEST
signal in the hippocampus, a region that primarily drives
the memory functions, and then slowly declined over
more than 1 h as shown in the representative scans
(Fig. 3d). APP/PS1 mice showed a low hippocampal glucoCEST signal compared to non-Tg mice. The area under
curve (AUC) of glucoCEST for APP/PS1 mice was 55%
lower than non-Tg mice. The AUC was further reduced
in APP/PS1/Aβ-Th1 mice (p < 0.01, 87%). APP/PS1/
Aβ-Th17 mice showed 67% less AUC compared to nonTg mice. APP/PS1/Aβ-Th1 and APP/PS1/Aβ-Th17 mice
decreased AUC 72% and 26%, respectively, compared
to untreated APP/PS1 mice, but did not achieve significance. Thus, Aβ-Teffs decreased glucose uptake in the
hippocampus region of APP/PS1 mice paralleled their
abilities to accelerate memory impairment.
Aβ-Teffs promote systemic inflammation

The onset of systemic inflammatory responses has been
demonstrated decades before memory impairment and
subsequent neurodegeneration in AD [32]. Moreover, higher levels of serum inflammatory cytokines are
observed in individuals who after 20 years demonstrated
memory decline and decreased brain volume [33].
Such observations suggest that systemic inflammatory
responses play an important early role in AD pathology
before amyloid deposition and microglia activation in
the brain [2, 14, 15]. To determine the effects of Aβ-Teffs
on systemic inflammation, frequencies of different T
cell subsets and inflammatory cytokines were measured
in blood, spleen and lymph nodes after adoptive transfer. Although, frequencies of CD4+ and CD8+ T cells
were unchanged regardless of mouse strain or treatment
(Additional file 1: Fig. S3), the subset analysis revealed
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increased systemic pro-inflammatory markers. It was
hypothesized that systemic inflammatory responses predominantly arise from antigen-specific T cells present in
the periphery of experimental mice. Therefore, we tested
the frequency of Aβ reactive CD4+ T cells by stimulating lymph node cells with cognate antigen (Aβ) in presence of APCs. CD4+ T cells from non-Tg mice showed
very low binding with MHCII–peptide tetramer, suggesting the presence of few Aβ-CD4+ T cells during homeostasis (Fig. 4a). In untreated APP/PS1 mice, Aβ-CD4+
T cell frequency was slightly, though insignificantly,
higher compared to non-Tg mice (Fig. 4a). However,
APP/PS1/Aβ-Th1 and APP/PS1/Aβ-Th17 mice exhibited significantly higher levels of Aβ-MHCII tetramer
reactive CD4+ T cells compared to non-Tg and APP/
PS1 mice (p < 0.01). The results indicate that antigenrecognizing CD4+ T cell populations are sustained after
adoptive transfer of Aβ-Teffs and suggested a contributory role in systemic inflammation associated with AD.
Indeed, splenocytes isolated from APP/PS1/Aβ-Th1 and
APP/PS1/Aβ-Th17 mice and stimulated with phorbol12-myristate-13-acetate (PMA) and ionomycin secreted
significantly higher levels of pro-inflammatory cytokines
TNFα (p < 0.05) and IL17 (p < 0.001) compared to splenocytes isolated from non-Tg and untreated APP/PS1 mice
(Fig. 4b). Additionally, APP/PS1/Aβ-Th1 mice secreted
significantly higher levels of IFNγ (p < 0.05) compared
to non-Tg and untreated APP/PS1 mice. Compared to
non-Tg controls, no differences in CD4+Tbet+ T cell
frequencies from APP/PS1 mice in any lymphoid compartment were detected, while CD4+RORγ+ T cell frequency was significantly increased in spleens of APP/
PS1 mice (p < 0.05) (Fig. 4c). CD4+Tbet+ T cells were
significantly elevated in spleen (p < 0.05) and lymph node
(p < 0.01) of APP/PS1/Aβ-Th1 mice compared to non-Tg
counterparts. Similarly, CD4+RORγ+ T cell frequencies were significantly increased in all tested lymphoid
compartments of APP/PS1/Aβ-Th1 mice (p < 0.01) while
in APP/PS1/Aβ-Th17 mice, CD4+RORγ+ T cell frequencies were significantly increased in blood (p < 0.05)
and spleen (p < 0.01) compared to non-Tg mice. In
lymph nodes, APP/PS1/Aβ-Th1 mice showed increased
CD4+Tbet+ (p < 0.05) and CD4+RORγ+ T cells
(p < 0.001) compared to APP/PS1 mice. Together, these
results highlight the potential of Aβ-specific Teffs to contribute to exacerbation of a pro-inflammatory environment in AD progression.
Aβ-Teffs affect Treg immunosuppression

Because afferent T cell and Teff responses modulate
regulatory T cell (Treg) frequency and function [2, 34,
35], we assessed the effects of Aβ-Teffs on Tregs, which
play important roles in the maintenance of immune
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Fig. 4 Adoptive transfer Aβ-Teffs affect systemic inflammation in APP/PS1 mice. Experimental mice were killed 6 weeks after Aβ-Th1 and Aβ-Th17
adoptive transfer. a Frequency of Aβ reactive CD4+ T cells among lymph node cells after stimulation with Aβ1–42 in presence of feeder cells using
fluorescently labeled MHCII-IAb-peptide tetramer. n = 4 mice per group were analyzed. b Frequency of intracellular pro-inflammatory cytokines
TNFα, IFNγ and IL17 from splenocytes after stimulation with PMA and ionomycin in the presence of brefeldin A. n = 6 mice per group were
analyzed. c Frequency of CD4+Tbet+ and CD4+RORγ+ T cells in blood, spleen and lymph nodes determined by flow cytometric analysis. n = 6
mice per group were analyzed. One-way ANOVA followed by Newman–Keuls post hoc test was used to determine statistical significance. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001
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tolerance against self- and non-self-antigens [2, 36].
Tregs suppress disease-reactive pro-inflammatory
T cell responses via their unique transcription factor forkhead box P3 (FOXP3) [6, 37]. Treg frequencies
were identified using surface and intracellular markers
CD4+CD25+FOXP3+ in different lymphoid compartments. APP/PS1 mice showed decreased frequency of
CD4+CD25+FOXP3+ cells (p < 0.01) in spleen compared to non-Tg mice (Fig. 5a). However, APP/PS1/
Aβ-Th1 mice showed decreased CD4+CD25+FOXP3+
T cell frequency in blood (p < 0.05), spleen (p < 0.001) and
lymph nodes (p < 0.05) compared to non-Tg mice, and
in spleen (p < 0.05) compared to APP/PS1 mice. As Treg
frequency does not always correlate with immunosuppressive function [38, 39], we sought to determine the
effects of Aβ-Teffs on the Treg-mediated function. Earlystage APP/PS1 mice (5–6 months old) showed slightly
increased Treg function (14%) compared to non-Tg
mice at higher concentrations (1:1) which might be due
to improved Treg function during early disease stages
(Fig. 5b) [40]. However, APP/PS1/Aβ-Th1 mice showed
significantly greater Treg dysfunction compared to nonTg (slope p = 0.3650, intercept p = 0.002) and APP/PS1
(slope p = 0.9954, intercept p < 0.0001) control mice at all
concentrations. Similar Treg dysfunction was observed
in APP/PS1/Aβ-Th17 mice at lower concentrations compared to Tregs from non-Tg and untreated APP/PS1
mice. Overall, results indicated that Aβ-Th1 cells and to
a lesser extent Aβ-Th17 cells diminished Treg frequency
and function and suggests that diminution of Treg medicated control contributes to increased pro-inflammatory
environment and on leads to the breakdown of immune
tolerance [41].
Aβ-Teffs induce Th1-dominant inflammatory responses
in the CNS

We determined the effect of Aβ-Teffs on the expression
of innate and adaptive immune genes within the CNS by
using transcriptomic analysis of RNA from hippocampi
of non-Tg and APP/PS1 mice treated with or without
Aβ-Teffs. Gene expression of Treg transcription factor
Foxp3 (p < 0.05) and anti-inflammatory cytokines Il10
and Il13 (p < 0.05) and chemokine Ccr8 were diminished
in APP/PS1/Aβ-Th1 and APP/PS1/Aβ-Th17 mice hippocampi compared to untreated APP/PS1 mice (Fig. 5c),
suggesting that adoptive transfer of Aβ-Teffs affect Tregs
not only in the periphery, but also in the CNS. The
inflammatory cytokine genes Il5, Il6, Ifng were decreased
while Tnf was increased (1.43-fold) in APP/PS1/Aβ-Th1
compared to APP/PS1 mice (Additional file 1: Fig. S4).
Importantly, Tbet encoding gene Tbx21 expression
increased in APP/PS1/Aβ-Th1 (2.59-fold) and APP/PS1/
Aβ-Th17 (1.32-fold) compared against APP/PS1 mice.
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Notably, RORγ encoding gene Rorc expression decreased
compared to non-Tg mice (Fig. 5c), underscoring predominate Th1 phenotype immune responses operative in
the brains of Aβ-Teffs-treated APP/PS1 mice.
Adoptive transfer of Aβ-Teffs into APP/PS1 mice
were studied for their abilities to induce changes in
selected biological processes. To elucidate these, functional and pathway enrichment analyses were performed in mice treated with Aβ-Th1 or Aβ-Th17 cells
then compared to non-Tg and APP/PS1 controls. Compared to non-Tg mice, Kyoto Encyclopedia of Genes
and Gnomes (KEGG) analysis of APP/PS1, APP/PS1/
Aβ-Th1 and APP/PS1/Aβ-Th17 mice demonstrated
alterations in the cytokine–cytokine receptor interactions, IL17, TNF, chemokines, Toll-like receptor
(TLR), Th17 cell differentiation, antigen processingpresentation, and Jak–STAT signaling pathways. There
was greater enrichment of the TLR signaling pathway
in APP/PS1/Aβ-Th1 mice. APP/PS1/Aβ-Th17 mice
showed higher Th1, Th2, and Th17 cell differentiation
pathways compared to APP/PS1 controls (Fig. 5d).
These data, taken together, suggest that chronic CNS
inflammatory responses are induced by Aβ-Th1 and
Aβ-17 cells. APP/PS1/Aβ-Th17 mice also showed an
enrichment of nuclear factor-kappa B (NF-κB) signaling pathway, which serves as a central mediator of
inflammation because promoter regions of several proinflammatory molecules have been found to contain
the DNA binding site for NF-κB [42]. Reactome analysis of different AD groups compared to non-Tg mice
showed enrichment of cytokine signaling in immune
system with higher induction in APP/PS1/Aβ-Th17
mice, while Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING) analysis showed enrichment
of networks such as TLR signaling pathway; regulation
of TNFR1 signaling, T cell chemotaxis; CC chemokine
receptor 5, Toll/IL1 receptor homology (TIR) domain;
and IL1-mediated signaling pathways with higher
enrichment in APP/PS1/Aβ-Th1 mice compared to
untreated APP/PS1 mice. Compared to untreated APP/
PS1 mice, KEGG analysis showed enrichments of Th1,
Th2, and Th17 cell differentiation, Jak–STAT, TCR,
and cytokine–cytokine receptor pathways in APP/PS1/
Aβ-Th1 mice, while IL17 signaling was enriched in
APP/PS1/Aβ-Th17 mice (Fig. 5e). Th1, Th2 and Th17
cells are critical mediators of neuroinflammatory diseases and have been associated with the pathogenesis
of several autoimmune diseases [43]. Reactome Gene
Set Enrichment Analysis (GSEA) analysis showed
enrichment of cytokine signaling in APP/PS1/Aβ-Th1
and APP/PS1/Aβ-Th17 mice compared to untreated
APP/PS1 controls. These data indicated enhanced
cytokine mediated pathogenesis in Aβ-Teff-treated
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Fig. 5 Aβ-Teffs affect Treg frequency and function. a Frequency of CD4+CD25+FOXP3+ Tregs in blood, spleen and lymph nodes from n = 6
mice per group. Statistical differences were determined using one-way ANOVA followed by Newman–Keuls post hoc test. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001. b Immunosuppressive function of Tregs assessed against proliferating CFSE-stained Tresps isolated from non-Tg mice.
Tregs were isolated and pooled from within each group (n = 6 mice per group) and experiment was performed in triplicate. Linear regression
analyses of Treg function from non-Tg mice showed r2 = 0.28 and p = 0.07. All other APP/PS1 groups showed r2 > 0.65 and p < 0.01. Although slops
are not significantly different between different experimental groups, Th1 mice showed significantly different intercepts compared to non-Tg
(p < 0.01) and APP/PS1 (p < 0.0001) mice. c Transcriptomic analyses for expression of innate and adaptive immune genes was performed using
the RNA isolated from hippocampal tissues. Heat maps of fold changes in expression of genes compared to untreated or Aβ-Teff-treated APP/PS1
mice with non-Tg mice (left panel) and APP/PS1/Aβ-Th1 and APP/PS1/Aβ-Th17 mice compared to untreated APP/PS1 mice with significant p value
provided in appropriate box (right panel). n = 4 mice per group analyzed using Qiagen RT2-PCR array. d, e Functional and pathway enrichment
analysis of transcriptomic dataset was performed using KEGG, Reactome and STRING database. Different immune and inflammatory pathways
affected in APP/PS1/Aβ-Th1 and APP/PS1/Aβ-Th17 mice were plotted as a bar chart in comparison to non-Tg (d) and untreated APP/PS1 mice (e).
Significant pathways with p value passing Bonferroni-corrected significant level of 0.05 were plotted

mice. Additionally, STRING analysis showed enrichment of immune-related networks of interacting genes
in Aβ-Th1 and Aβ-Th17-treated mice compared to
untreated APP/PS1 mice. These data indicate that activated immune and inflammatory responses are exacerbated in Aβ-Teff adoptive transferred mice when
compared to non-Tg and APP/PS1 controls.

Aβ-Th1 cells facilitate amyloid deposition

Amyloid plaque forms upon sequential cleavage of
APP attributed to different secretase enzyme activities. Before assessment of amyloid, we determined the
effects of Aβ-Teffs on expression of full-length APP.
Western blot analysis showed unaltered expression of
full-length APP assessed by 6E10 and 22C11 in all APP/
PS1 mice irrespective of Aβ-Teffs treatment (Fig. 6a). As
amyloid plaque develops by aggregation of soluble Aβ
oligomers, which are toxic and contribute to memory

Machhi et al. Journal of Neuroinflammation

(2021) 18:272

impairment [6], we next assessed the expression of soluble human Aβ1–40 and Aβ1–42 levels in cortical brain
tissues from APP/PS1 mice. Aβ1–40 levels significantly
increased in APP/PS1/Aβ-Th1 (p < 0.01) and APP/PS1/
Aβ-Th17 (p < 0.01) mice compared to untreated APP/
PS1 mice (Fig. 6b). Similarly, Aβ1–42 levels significantly
increased in APP/PS1/Aβ-Th1 (p < 0.05) and APP/PS1/
Aβ-Th17 (p < 0.05) mice compared to APP/PS1 mice.
APP/PS1 mice develop amyloid plaque in the brain as
early as 3 months of age [44], therefore we evaluated
the effects of Aβ-Teffs on the amyloid plaque deposition
in mice brain by immunohistochemistry which showed
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remarkable increases in amyloid plaque deposition in
Aβ-Teffs-treated APP/PS1 mice (Fig. 6c). Indeed, total
amyloid plaque loads increased in both cortex (53%) and
hippocampus (p < 0.05) of APP/PS1/Aβ-Th1 mice compared to those of untreated APP/PS1 mice. APP/PS1/
Aβ-Th17 mice showed total amyloid plaque loads 32%
and 37% greater than APP/PS1 controls in cortex and
hippocampus, respectively, but did not attain significance. The area occupied by the dense amyloid plaques
was determined by Thioflavin-S staining of the same
brain sections used for immunohistochemistry from different APP/PS1 mice. APP/PS1/Aβ-Th1 mice showed

Fig. 6 Aβ-Th1 and Aβ-Th17 cells increase amyloid load in APP/PS1 mice. a Western blot analysis performed to determine expression of full-length
APP using cortical tissue lysate and 22C11 and 6E10 antibodies. Representative immunoblot and densitometric quantification was performed using
different APP/PS1 mice. n = 4 mice per group were analyzed for statistical significance using one-way ANOVA followed by Newman–Keuls post hoc
test. b ELISA performed to quantify Aβ1–40 and Aβ1–42 levels in the brain using Tris–HCl soluble fractions of cortical tissue. c Immunohistochemistry
(pan-Aβ) and immunofluorescence (Thioflavin-S) performed to determine the area occupied by the insoluble Aβ plaque in the cortex and
hippocampal brain regions. Representative images showing amyloid plaque DAB and Thioflavin-S staining in different brain regions. Percentage
occupied area quantified using Cavalieri estimator probe of Stereo Investigator system (MBF Bioscience). Scale bar = 100 µm. n = 6 mice per group
were analyzed. Statistical differences between groups determined using one-way ANOVA followed by Newman–Keuls post hoc test. *p < 0.05,
**p < 0.01
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significantly increased dense amyloid plaque loads in
cortex (p < 0.05, 86%) and hippocampus (p < 0.01, 134%)
compared to APP/PS1 controls, while APP/PS1/Aβ-Th17
mice showed dense amyloid plaque loads 47% and 64%
higher than APP/PS1 controls in cortex and hippocampus, respectively, but without significance. The results
highlight that Aβ-Teffs drive amyloidosis in the APP/PS1
mice brain via aberrant APP cleavage without affecting
APP production.
Aβ-Th1 cells activate microglia

Microglia activation is a unique signature of neuroinflammation observed in AD patients and animal models
[8], thus to determine the effects of Aβ-Teffs on microglial responses, we counted Iba1-reactive cells with
amoeboid morphology in the cortex and hippocampus
of different treatment groups. Immunohistochemistry
visually showed that untreated APP/PS1 mice exhibited
substantially more Iba1 positive (Iba1+) amoeboid cells
compared to non-Tg mice suggesting microglial activation in early-stage AD mice (Fig. 7a). Moreover, remarkable numbers of reactive microglia were also observed in
cortex and hippocampus of APP/PS1/Aβ-Th1 and APP/
PS1/Aβ-Th17 mice. Stereological quantification revealed
significantly increased numbers of Iba1+-reactive microglia in the cortex (p < 0.01) and hippocampus (p < 0.01) of
untreated APP/PS1 mice brain compared to non-Tg mice
(Fig. 7b). APP/PS1/Aβ-Th1 mice showed higher microglia activation in the cortex and hippocampus (p < 0.01)
even compared to untreated APP/PS1 mice. APP/PS1/
Aβ-Th17 mice also exhibited levels of reactive microglia in the cortex and hippocampus that were 16% and
29% higher, respectively, than untreated APP/PS1 mice,
but did not attain statistical significance. To gain greater
insights into microglia activation states, expression of
the classical (M1) and alternative (M2) microglia activation markers inducible nitric oxide synthase (iNOS) and
arginase-1, respectively [6, 9] was assessed in cortical tissues from experimental mice by western blot analysis. In
early-stage disease of APP/PS1 mice, iNOS levels were
elevated and arginase-1 levels diminished, though not
statistically compared to non-Tg mice (Fig. 7c). However,
APP/PS1/Aβ-Th1 mice showed increased production
of iNOS, while adoptive transfer of Aβ-Th1 or Aβ-Th17
Teffs significantly reduced arginase-1 levels in recipient APP/PS1 mice (p < 0.05). These results revealed that
Aβ-Teffs adoptive transfer potentiates progressive proinflammatory (M1) microglia activation status in APP/
PS1 mice brain, wherein Aβ-Th1 cells are more capable of
affecting microgliosis than Aβ-Th17 cells.
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Aβ-Th1 cells affect neuronal progenitor cell numbers
and function

Hippocampal neurogenesis correlates with memory
function and neural plasticity; all affected during AD
progression [45, 46]. To examine the effects of Aβ-Teffs
on neurogenesis during AD progression, we assessed
doublecortin (Dcx) as a biomarker of neuronal progenitors of the hippocampus [6, 45]. Dcx+ cell frequency was
significantly diminished by 72% in the dentate gyrus of
untreated APP/PS1 mice brain compared to non-Tg mice
(p < 0.001, Fig. 8a). Adoptive transfer of Aβ-Teffs further
reduced numbers of Dcx+ progenitors, compared to
non-Tg controls (p < 0.001), but were not significant compared to APP/PS1 mice (32%). Next, we assessed expression of presynaptic (synaptophysin) and postsynaptic
[postsynaptic density protein 95 (PSD95)] neurons in
cortical brain lysates by western blot analysis. Co-expression of both pre- and post-synaptic proteins is essential
for neuroplasticity, and therefore alteration of either protein level affects memory [6, 47]. Immunoblot quantification revealed that synaptophysin and PSD95 levels were
unaltered in untreated APP/PS1 mice compared to nonTg mice (Fig. 8b). However, expression of synaptophysin
was reduced in APP/PS1/Aβ-Th1 (27% not significant)
and APP/PS1/Aβ-Th17 (p < 0.05, 45%) mice compared to
non-Tg mice. Additionally, APP/PS1/Aβ-Th1 (p < 0.05),
but not APP/PS1/Aβ-Th17 mice showed reduced expression of PSD95 compared to non-Tg mice. Thus, only
presynaptic protein abnormalities were observed in APP/
PS1/Aβ-Th17 mice, while pre-and post-synaptic protein
densities were affected in APP/PS1/Aβ-Th1 mice. Overall, Aβ-Th1 and Aβ-Th17 cell-mediated exacerbation of
neuronal synaptic disintegrity in amyloid-rich environments which contribute to Aβ-Teffs’ potential to accelerate memory impairment in APP/PS1 mice.

Discussion
Previous studies demonstrated a spectrum of effects
for Aβ-reactive Teffs in animal models and AD patients
[17–19, 48, 49]. However, one of the limitations of those
studies is that polyclonal Teffs used were short-term
maintained (2 to 4 weeks), unstable, and prone to plasticity, which are not ideal for the study of T cell processes in
AD and their underlying complex mechanism of actions.
The polyclonal cells, unlike cloned populations, contain
mixtures of several putative, but unexpressed phenotypes, which could overwhelm the population during the
short culture time or possibly be eliminated. Therefore,
we generated stable, long-lived Aβ-Th1 and Aβ-Th17 Teff
clones, which were maintained for more than 6 months
without compromising cytokine signatures and antigen
specificities prior to use in in vivo experiments. Adoptive transfer of Aβ-Th1 and Aβ-Th17 Teffs exacerbated
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Fig. 7 Aβ-Th1 and Aβ-Th17 cells activate microglia in APP/PS1 mice. a Immunohistochemistry performed to quantify number of reactive Iba1+
microglia cells in cortex and hippocampus brain regions. Representative pictures showing Iba1-reactive cells in different brain regions. Scale
bar = 100 µm. Area with most Iba1-reactive cells highlighted by inserts for the cortex and hippocampus. Microglia morphology shown in higher
magnification images. Scale bar = 20 µm. b Number of Iba1+-reactive microglia cells were quantified using optical fractionator module of Stereo
Investigator system (MBF Bioscience). n = 5 mice per group were analyzed. c Western blot analysis performed to determine expression of iNOS and
arginase-1 using cortical tissue lysate for assessment of microglial phenotypes. Representative immunoblot and densitometric quantification were
performed using n = 4 mice per group. Statistical significance between different experimental groups determined using one-way ANOVA followed
by Newman–Keuls post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

memory impairment and amyloid deposition in APP/PS1
mice. The results vary with a previous report where only
IFNγ-secreting Aβ-Th1 cells produced detrimental memory effects in APP/PS1 mice [18]. One possible explanation is that instead of independent development, we
polarized Aβ-Th1 cells into Aβ-Th17 Teffs using selective
culture media. Adoptive transfer of Aβ-Th17 cells may

have induced a combined Th1/Th17 Teff pathogenesis
via IFNγ and IL12 signaling [50]. In agreement with our
results, clinical studies have shown increased frequency
of IFNγ secreting Th1 [51] and IL17-secreting Th17
cells [14, 15] in the early-stage AD patients compared to
healthy controls. Our own and other laboratories have
demonstrated neurotoxic effects of antigen-specific
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Fig. 8 Aβ-Th1 and Aβ-Th17 cells affect neurogenesis and synaptic plasticity in APP/PS1 mice. a Neuronal progenitor cell density determined by
immunohistochemical staining of doublecortin positive (Dcx+) cells in the dentate gyrus region of the hippocampus. Representative images
showing Dcx+ cells. Scale bar = 20 µm. Dcx+ cells were quantified using the optical fractionator module of Stereo Investigator system (MBF
Bioscience). n = 6 mice per group were analyzed. b Western blot analyses performed to determine expression of presynaptic (synaptophysin) and
postsynaptic (PSD95) neurons using cortical tissue protein. Representative immunoblot and densitometric quantification performed for n = 4
mice per group. Statistical significance between groups determined using one-way ANOVA followed by Newman–Keuls post hoc test. *p < 0.05,
****p < 0.0001

Th17 cells in PD animal models [34] and patients [39].
Indeed, peripheral adaptive immune impairments are
comparable between the two most common neurodegenerative diseases, AD and PD [35, 39, 52], and has been
speculated that disease operative Th17 cells are also deleterious, although to a lesser extent than Th1 cells in AD
pathogenesis.
Systemic inflammation is operative in AD patients
before the onset of memory impairment. This suggests
an important role of peripheral immune activation in

disease [15, 32, 33]. Aβ drains to the peripheral cervical
lymph nodes [53] where APCs process and present Aβ
peptides to peripheral T cells engaging MHC-I or -II,
which initiates peripheral adaptive immune activation
[2, 11, 54]. However, with disease progression, Aβ lymphatic drainage is compromised leads to the formation of
cerebral amyloid angiopathy and Aβ accumulation [55].
In parallel, clonally expanded and activated peripheral
T cells expressing chemokines (CCL3, CCL4) cross the
blood–brain barrier (BBB) and affect resident microglia
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and neuronal cells perpetuating a neuroinflammatory
state [21, 56]. Recently, Gate et al. showed elevated frequency of CD8+ effector memory T cells in the blood of
AD patients which negatively correlated with memory
function [13]. The peripheral CD8+ Teffs invaded the
CNS, clonally expanded into the cerebrospinal fluid, and
contributed to neuroinflammation [13]. Here, adoptive
transfer of Aβ-Th1 and Aβ-Th17 Teffs into APP/PS1 mice
increased the frequency of antigen-specific T cells. This
was demonstrated by increased expression of TNFα-,
IFNγ- and IL17-secreting and MHCII-IAb-Aβ peptide tetramer reactive CD4+ T cells. Elevated Th1 and
Th17 cytokines then weaken tight junctions of the BBB
to allow peripheral inflammatory mediators, including
TNFα, IL1β, and IL6, entrance into the brain serving to
further activate resident microglia. We contend that reactive microglia contribute to aberrant adaptive immune
responses by presenting cognate antigen and secreting
pro-inflammatory cytokines [57]. The direct involvement
of Aβ-Teff-induced systemic inflammatory responses in
the neuroinflammatory cascade and amyloid deposition
is a pivotal pathogenic process for AD.
Previous studies reported decreased frequency and
function of anti-inflammatory and immunosuppressive
CD4+CD25+FOXP3+ Tregs in blood of AD patients
[52, 58] and experimental animal models [6]. Additionally, transient breaking of immune tolerance by Treg
depletion is associated with amyloid clearance and neuroinflammation restoration via subsequent CNS recruitment of immunoregulatory Treg and monocyte-derived
macrophages [41]. Other reports demonstrated the neuroprotective potential of polyclonal Treg-adoptive transfer or expansion in AD animal models [59, 60], PD [61,
62], and ALS patients [63]. Together, these reports suggest a role of Treg deficits in AD progression, but the
underlying cause is unknown. For the first time, we identified the role of disease operative CD4+ Aβ-Teff subsets
in Treg dysfunction in APP/PS1 mice. We demonstrated
that adoptive transfer of Aβ-Th1 and Aβ-Th17 cells significantly reduced the frequency of CD4+CD25+FOXP3+
Tregs in blood, spleen and lymph nodes of APP/PS1
mice. Additionally, Treg immunosuppressive function
was greatly compromised in APP/PS1 mice receiving
Aβ-Th1 cells compared to Aβ-Th17 treated or untreated
APP/PS1 mice. Interestingly, Aβ-Teffs affected Treg
function in both periphery and CNS. It is speculated
that antigen-specific CD4+ T cells detected after adoptive transfer elicited Treg impairments to progress AD
pathology in mice [2, 64].
Microglia serve key roles in processing and presenting self-antigens including Aβ to T cells to maintain
immune tolerance [2, 19]. Non-activated microglia
exhibit ramified morphology and are able to clear Aβ
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deposits through phagocytosis. However, with disease progression, microglia become more activated
and acquire amoeboid morphology with compromised
phagocytic capabilities [9]. Upon antigenic stimulation,
microglia can acquire either classically activated (M1)
or alternatively activated (M2) phenotype, representing
pro-inflammatory and anti-inflammatory phenotypes,
respectively [6, 9]. Here, we identified that expression
of iNOS, an M1 marker, was significantly elevated while
that of arginase, an M2 marker, was reduced in the
brain of APP/PS1/Aβ-Th1 mice, suggesting that diseaselinked CD4+ Teffs alter microglial polarization leading
to worsen disease outcomes. Recently, using genomewide analysis and single-cell mass cytometry [65, 66],
different microglial clusters were identified in various
brain regions of humans and mice and were found to
predominantly exist distinctly to the physiological and
pathological conditions. However, the unique function
associated with each microglia subset has not yet been
identified. These reports suggest that microglia phenotypes are much more complicated and beyond simplified
M1 and M2 phenotypes [67, 68]. Functional and pathway
enrichment analysis revealed that Th1, Th2 and Th17,
and cytokine and TLR signaling pathways are enriched
in APP/PS1 mice brain following adoptive transfer of
Aβ-Teffs further confirming the ability of Aβ-Teffs to perpetuate immune and neuroinflammatory responses.
In addition to affecting microglia responses, Aβ-Th1
cells significantly increased amyloid deposition in both
cortex and hippocampus regions of brain as demonstrated by increased soluble Aβ1–40 and Aβ1–42 as well as
insoluble Aβ plaques without affecting full-length APP
production. Aβ-Th17 cell treatment affected amyloid
load and microglial responses in APP/PS1 mice brain to
a lesser extent compared to Aβ-Th1 cells which might
be due to their less extensive inflammatory responses as
those induced by Aβ-Th1 cells in an amyloid-rich environment. The results were further supported by the
previous study showing Th1 biased immune responses
accountable for most of the CD4+ Teffs’ detrimental
effects in APP/PS1 mice [18]. Neuroinflammation arose
either as a result of Teff-driven microglia responses or
through direct cytokine release [2, 11] affecting synaptic integrity and neurogenesis. These are both hallmarks
of neurodegeneration [6, 9]. Functional co-localization
of pre- and post-synaptic neurons is essential for memory development, whereby defects in either neuron can
worsen memory function [9, 47]. Adoptive transfer of
Aβ-Th1 and Aβ-Th17 cells showed significantly defective post-synaptic protein expression in APP/PS1 mice.
Neuronal progenitor development is affected in the dentate gyrus region of APP/PS1 mice, which was further
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worsened by Aβ-Teffs, suggesting Aβ-Teffs impose a detrimental role in neurogenesis.
A previous study demonstrated that complete loss of
peripheral adaptive immune system exacerbated amyloid
deposition and neuroinflammation in 5XFAD-Rag mice
and that reconstitution of this cell population restores
AD pathology [7]. Likewise, from HIV infected individuals, 50% of patients develop AD-linked memory deficits
later in life despite antiretroviral therapy, in part due to
selective functional decline of peripheral CD4+ T cells
[69]. Although, adaptive immune T cells are essential
to control AD pathology, Aβ-reactive Teffs can develop
meningoencephalitis as evidenced in a Phase IIa clinical trial (NCT00021723) with full-length Aβ immunization in QS21 adjuvant [48, 49]. Indeed, considering
studies of the CNS effects of Aβ-Teffs in AD patients and
animal models [19, 49], ours is the first study characterizing effects of stable, long-lived Aβ-Th1 and Aβ-Th17
Teff clones on neuroinflammation in the AD mouse
model. We identified that Aβ-Th1 cells induced consistent pro-inflammatory responses in both periphery and
CNS leading to memory impairment, increased amyloid
load, microgliosis, and impaired neurogenesis. Tregs
were identified as a key regulator of Aβ-Teff-driven neuroinflammation in amyloid-rich environment leading to
the breakdown of immune tolerance [2, 41]. Thus, we
postulate that development of Aβ-specific Tregs, instead
of polyclonal Tregs associated with the risk of global
immunosuppression [70] might better serve as a safe and
potential therapeutic alternate for management of elderly
AD patients.

Conclusions
Disease-reactive Aβ-Th1 and Aβ-Th17 cells transform a
pro-inflammatory microenvironment to accelerate AD
pathology in APP/PS1 mice. The detrimental effects
of Aβ-Teffs are sped by limiting Treg activities in the
periphery and CNS. Control of this neurodestructive
environment represents a potential therapeutic strategy
and can be sped by augmenting peripheral Treg numbers
and function reactive against disease-specific protein.
Methods
Development of Aβ-Th1 and Aβ-Th17 cells

Six-month-old, two female B6;129 mice were immunized
by subcutaneous injection with human Aβ1–42 (50 µg)
(Catalog no. 03-112, Life Technologies) emulsified in
complete Freund’s adjuvant (Sigma Aldrich) containing
Mycobacterium tuberculosis (1 mg/ml). The mice were
boosted after 2 weeks with Aβ1–42 (50 µg) in incomplete
Freund’s adjuvant (Sigma Aldrich). One week after the
second immunization, the mice were killed, and spleen
and lymph nodes (axial, brachial, cervical, and inguinal)
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were harvested then mashed through 70-μm cell strainer
to prepare single cell suspensions. The red blood cells
were lysed with ammonium–chloride–potassium (ACK)
lysis buffer (Catalog no. A10492, Thermo Fisher Scientific). CD4+ T cells were enriched from single cell
suspensions using an EasySep™ mouse CD4+ T cell isolation kit (Catalog No. 19852, Stemcell Technologies) and
recovered CD4+ T cells (98% CD4+ by flow cytometric
analysis) were cultured in vitro in the presence of monomeric Aβ1–42 (25 μg/ml) prepared as described before
[71] (Catalog no. RP10017, GenScript) and 2.5 × 107
feeder cells, i.e., splenocytes isolated from naïve female
B6;129 mice and irradiated at 3200 Gy (RS 2000 Irradiator, Rad Source, Buford, GA). Cells were propagated in
RPMI-1640 media supplemented with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 25 mM HEPES, 1 mM
sodium pyruvate, 1× nonessential amino acids, 55 nM
2-mercaptoethanol, 100 U/ml penicillin, and 100 µg
streptomycin. Fresh culture media, Aβ, and feeder cells
were provided weekly and the viable CD4+ T cells were
counted before each passage. CD4+ T cells non-reactive to Aβ were eliminated over passages as evidenced
by declined viable CD4+ cell count up to day 21 (Additional file 1: Fig. S1a). On day 28, increased Aβ-reactive
CD4+ T cell count was observed and at this point 25 U/
ml interleukin-2 (IL2) was added to the culture, leading
to further increase in Aβ-reactive CD4+ count thereafter. To recover CD4+ T cell clones, cells were cultured
at 1 cell/well in flat-bottom 96-well plate in presence of
fresh feeder cells and Aβ1–42. The most rapidly growing
Aβ-reactive clone was identified and propagated with
IL2, Aβ1–42, and feeder cells, and hereafter is designated
as Aβ-Th1 cells. A subclone of Aβ-Th1 was polarized to
Th17-type Teffs by culturing in complete RPMI media
supplemented with 3 ng/ml TGFβ, 25 ng/ml IL6, 5 ng/
ml IL1β, 20 ng/ml IL23 and 3 µg/ml of antibodies to IL4,
IFNγ, and IL2 in the presence of Aβ1–42 and fresh feeder
cells; hereafter designated as Aβ-Th17 cells.
Cell phenotypes and antigen-specificities

To induce cytokine production, 106 Aβ-Th1 or Aβ-Th17
cells were stimulated in complete RPMI-1640 media
containing 20 ng/ml PMA, 1 µM ionomycin (Sigma
Aldrich), and 3 µg/ml brefeldin A (Catalog no. 4506521,
eBioscience) for 12 h, then extracellular/intracellular
staining was performed for flow cytometric analysis
as described before [6, 72]. Cells were first stained for
surface biomarker expression with anti-CD3e-PE (Catalog no. 12003181, eBioscience), anti-CD4-APC-H7
(Catalog no. 560181, BD Pharmingen), and anti-CD8aPE-Cyanine 5.5 (Catalog no. 35008180, eBioscience)
antibodies for 30 min at room temperature. For intracellular staining, cells were fixed and permeabilized
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using transcription factor staining buffer kit (Catalog no. 552300, eBioscience) for 45 min at 4 °C, followed by incubation with anti-IFNγ-FITC (Catalog no.
11731182, eBioscience), anti-TNFα-eFluor 450 (Catalog
no. 48732182, eBioscience), anti-IL17a-Alexa Fluor 647
(Catalog no. 506912, BioLegend), anti-Tbet-eFluor 660
(Catalog no. 50582582, eBioscience) and anti-RORγPerCp eFluor 710 antibodies (Catalog no. 46698182,
eBioscience) for 30 min at 4 °C. Isotype and fluorescence-minus-one (FMO) controls for each antibody
were used during flow cytometric analysis for accurate
gating of different cell subsets. For analysis of extracellular cytokine release, Aβ-Th1 and Aβ-Th17 cells were
stimulated with 20 ng/ml PMA and 1 µM ionomycin
for 12 h and culture supernatants were analyzed using
proteome profiler mouse cytokine array kit (Catalog
no. ARY006, R&D Systems) according to the manufacturer’s instructions. CD3+CD4+ T cells were gated to
quantify the intracellular cytokine and transcription
factor expression. Few endogenous feeder cells were
present during extracellular immunoblot staining that
might have affected the cellular cytokine signature during short activation period.
From Aβ1–42 sequence, 1 to 15 amino acid region
(DAEFRHDSGYEVHHQ) comprises B cell epitope
while 15 to 30 amino acid region (KLVFFAEDVGSNKGA) comprises T cell epitope in the mice while
in human it may be up to 15 to 42 amino acid region
[51]. To elucidate the ability of Aβ-Th1 and Aβ-Th17
cells to recognize the T cell epitope of Aβ1–42 presented
by H-2b haplotypes (feeder cell matched), tetramers
were constructed with I-Ab and the amino acid 15–30
(MHCII-IAb–KLVFFAEDVGSNKGA) conjugated to
fluorophore BV421 (National Institute of Health (NIH)
Tetramer Core Facility, Emory University, Atlanta, GA).
MHCII-IAb–PVSKMRMATPLLMQA tetramer with no
Aβ specificity was used as control. For tetramer staining, 3 × 105 Aβ-Th1 or Aβ-Th17 cells were incubated
with increased concentrations of MHCII-IAb–KLVFFAEDVGSNKGA Aβ tetramer (1.2 µg, 2.4 µg and
12 µg) or MHCII-IAb–PVSKMRMATPLLMQA control tetramer (2.4 µg) for 3 h at 37 °C. After incubation,
tetramer-stained T cells were reacted with anti-CD3ePE and anti-CD4-APC-H7 antibodies for 30 min at
room temperature, followed by live-dead staining with
propidium iodide (0.5 µg/ml) for 5 min at room temperature. Stained T cells were analyzed with a LSR II
flow cytometer and FACSDiva Software (BD Bioscience) at the University of Nebraska Medical Center
Flow Cytometry Research Facility.
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T cell receptor identification

Total RNA was isolated from the parent T cell clone (AβTh1 cells) using RNAeasy mini kit (Catalog no. 74104,
Qiagen). First strand complementary DNA (cDNA) was
synthesized and TCRα and TCRβ chain variable region
sequences were amplified using SMARTer® mouse TCR
a/b profiling kit (Catalog no. 634402, Takara). For the
TCR sequence identification, PCR products generated
were cloned into the pCR™ 4Blunt-TOPO® plasmid using
Transform One Shot® Mach-T1™ competent cells following manufacturer’s instructions (Catalog no. 450031, Life
Technologies). Bacterial colonies were grown in LB agar
media followed by DNA isolation and clean-up using
monarch plasmid miniprep kit (Catalog no. T1010S,
New England BioLabs) and samples were submitted for
Sanger sequencing with M13 primers at the University of
Nebraska Medical Center Genomics Core Facility.
Modeling of TCR–pMHC complex

The TCR-Aβ–MHCII (TCR–pMHC) complex was constructed with the fully automated structure preparation
and homology modeling in the Schrodinger BioLuminate
suite [73]. The loops were modeled using ab initio loop
modeling and cross validated on the SwissModel server
[74, 75]. The quality estimation of the generated model
and subsequent refinements were performed by MolProbity and QMEAN method on SwissModel [76]. The full
query sequence was used for the modeling studies, MHC
consisted of two chains: MHCII-IAbα with 256 residues
(1–256) and MHCII-IAbβ with 264 residues (257–521).
Aβ peptide had 42 residues (522–563), TCRα consisted of
274 residues (564–838) and TCRβ consisted of 305 residues (839–1144). The MHC–peptide residues were first
modeled with the antibody modeling tools prediction
and advanced homology modeling. The TCRα/β complex was modeled later and both models were analyzed
separately for structural features. The single model was
generated from the above-mentioned tools, the structural features were validated from the previously generated models. System preparation: All molecular dynamics
(MD) simulations were performed on AMBER 18 software package [77]. The protein complex was prepared
with the help of XLeap [78]. The TCR–pMHC complex was solvated in a truncated octahedron box unit of
dimensions x = 192.98, y = 186.34 and z = 182.65. Total of
125,812 TIP3P water molecules were added to solvate the
system [79]. A sufficient number of counter ions, Na+
and Cl−, were added to neutralize the simulation system
and achieve 0.14 M of ionic strength. FF14SB force field
was used to parameterize the amino acids and to model
the proteins [80]. Unbiased explicit solvent MD simulation: Simulations were performed for 100 ns of time
step on Nvidia V100-SXM2-16 GB Graphic Processing
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Unit using the PMEMD.CUDA module [81]. Simulations were run at 1 atm constant pressure using Monte
Carlo barostat and 300 K constant temperature by using
Langevin thermostat with a collision frequency of 2 ps-1
and the volume exchange was attempted for every 100 fs.
An integration step of 2 fs was also used for simulation
of hydrogen atoms involving bonds were constrained by
using SHAKE algorithm [82]. Long-range electrostatic
interactions were computed using Particle Mesh Ewald
method while for short-range interaction a cutoff of 8 Å
was used [83]. Equilibration consisted of rounds of NVT
and NPT equilibration for 10 ns in total. CPPTRAJ [84]
was used to analyze the interactions over full trajectory
after taking configuration at every 4 ps. RMSD, RMSF
was determined after analyzing the trajectories.
Adoptive transfer in APP/PS1 mice

All animal experiments were approved by the institutional Animal Care and Use Committee of University of
Nebraska Medical Center. Transgenic mice overexpressing human APP695 with the Swedish mutation (Tg2576)
were obtained from Drs. G. Carlson and K. Hsiao-Ashe
through the Mayo Medical Venture [85]. PS1 mice overexpressing human PS1 with M146L mutation were provided by Dr. K. Duff through the University of South
Florida [86]. Both mice were maintained on the B6;129
hybrid background. Male Tg2576 mice were crossbred
with female PS1 mice to generate APP/PS1 double-transgenic mice and non-transgenic (non-Tg) B6;129 mice
were developed in parallel as described previously [6, 9,
87, 88]. Female APP/PS1 mice, 4–5 months old, and agematched non-Tg littermates were randomly divided into
the different experimental groups. Either 1 × 106 Aβ-Th1
or Aβ-Th17 cells in 100 µl phosphate-buffered saline
(PBS) were adoptively transferred to the APP/PS1 recipient mice, intravenously via tail vein using a 28-gauge needle affixed to a sterile tuberculin syringe, twice at 1-week
intervals. Untreated and age-matched non-Tg mice
served as control.
Radial arm water maze test

Two weeks after the second adoptive cell transfer, mice
were submitted for radial arm water maze (RAWM) testing in a blinded fashion to assess memory impairment as
previously described [6, 71]. Briefly, mice from masked
cages were introduced into the circular water filled tank
(diameter-110 cm and height-91 cm, San Diego Instruments) with triangular inserts that produce six swim
paths radiating from the center. Special cues are fixed on
the tank wall to guide mouse orientation. At the end of
any one arm, a circular Plexiglass hidden platform (diameter-10 cm) is placed submerged 1 cm beneath the water
level. The platform was placed in the same arm for four
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consecutive acquisition trials (T1–T4), and retention
trial (T5), but in a different arm on different experimental days. For T1–T4, the mouse started the task from a
randomly chosen arm without a platform. After four trials, the mouse was returned to its cage for 30 min and
reintroduced into the T4 arm, for the delayed retention trial (T5). Each trial lasted 1 min, and an error was
scored when mouse entered the wrong arm; entered the
arm with the platform, but did not climb on it; or did not
make a choice for 20 s. The trial ended when the mouse
climbed and stay on the platform for at least 10 s. The
mouse allowed to rest on the platform for 20 s between
trials. If the mouse did not climb the platform, after 60 s
it was gently guided to the submerged platform. The
T1, T4 and T5 trial errors over 9-day test were divided
into three blocks (block-1 days 1–3, block-2 days 4–6,
block-3 days 7–9), and the errors in each block were
averaged for statistical analysis.

2-Deoxy glucose chemical exchange saturation transfer
(glucoCEST) MRI

Mice were fasted for 24 h and fasting blood glucose concentrations were measured prior to the experiment using
glucometer and test strips (ReliOn™ Prime) by collecting
blood from tail vein puncture. Mice were anesthetized
with isoflurane in the mixture of oxygen and the peritoneal cavity was cannulated for the injection of 2-deoxy
glucose (2DG). Cannulated mice were fixed on a 1H magnetic resonance imaging (MRI)-compatible cradle using a
bite bar. MRI was performed on a 7-Tesla scanner (Bruker
PharmaScan, Billerica, MA) with a Bruker-built quadrature mouse brain RF coil. Respiration and body temperature were monitored during scanning. A baseline glucose
CEST (glucoCEST) MRI was acquired followed by 2DG
(1 g/kg in PBS) injection via intraperitoneal catheter into
the mice to monitor glucose signal in the brain over the
time. GlucoCEST data were acquired using a rapid acquisition with relaxation enhancement (RARE) sequence
(repetition time (TR)/echo time (TE) = 1600/16 ms,
RARE factor = 8) with a continuous radio frequency (RF)
for saturation with the power = 3 µT, duration = 1 s, saturation frequencies = − 1600 to 1600 Hz in steps of 80 Hz.
A second CEST data with saturation RF power = 0.5 μT,
and frequencies = − 300 to + 300 Hz were acquired for
B0 inhomogeneity correction using WASSR [89]. The
glucoCEST scan time was ~ 10 min, and was repeated at
10, 20, 30, 40, 50, and 60 min after 2DG injection. Asymmetric magnetization transfer ratio (MTRasym) was
calculated from the Z-spectrum that was built based on
CEST data. The glucoCEST signal was calculated as the
integral of the MTRasym within 1.00 ± 0.25 p.p.m.
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Flow cytometry

On day 42, mice were terminally anesthetized with
pentobarbital followed by spleen isolation in complete
RPMI media and blood collection via cardiac puncture in
the K3EDTA tubes (Catalog no. 450475, Greiner BioOne
North America). Lastly, mice were pericardially perfused with PBS and lymph nodes (axial, brachial, cervical, and inguinal) and brain were harvested. Whole blood
was stained while single cell suspension was prepared
from spleen and lymph nodes. Either 50 μl of blood or
1 × 106 spleen or lymph node cells were stained for flow
cytometric analysis as described above using antibodies: anti-CD3e-PE, anti-CD4-APC-H7, anti-CD8a-PECyanine 5.5, anti-CD25-PE-Cy7 (Catalog no. 25025182,
eBioscience), anti-Tbet-eFluor 660, anti-RORγ-PerCp
eFluor 710 and anti-FOXP3-Alexa Fluor 488 (Catalog no.
320012, BioLegend). For intracellular cytokine analysis,
1 × 106 spleen cells were stimulated with 20 ng/ml PMA
and 1 µM ionomycin in presence of brefeldin A for 12 h
and after incubation cells were stained with anti-CD3ePE, anti-CD4-APC-H7, anti-IFNγ-FITC, anti-TNFαeFluor 450, and anti-IL17a-Alexa Fluor 647 antibodies.
To determine the frequency of Aβ reactive CD4+ T cells,
1 × 106 lymph node cells were stimulated with Aβ1–42
(25 μg/ml) in presence of feeder cells and IL2 (25 U/
ml) for 5 days at 37 °C. On day 5, cells were collected by
centrifugation and incubated with MHCII-IAb–KLVFFAEDVGSNKGA Aβ tetramer (6 µg) or MHCII-IAb–
PVSKMRMATPLLMQA control tetramer (6 µg) for 3 h
at 37 °C. After incubation, T cell-MHCII-Aβ tetramer
complex was stained with anti-CD3e-PE, anti-CD4-APCH7 antibodies and propidium iodide for flow cytometric
analysis.
Treg function assay

CD4+CD25+ Tregs and CD4+CD25− T responder cells
(Tresps) were isolated from the mice spleen as described
earlier [72] using EasySep™ mouse Treg enrichment kit
(Catalog no. 18783, Stemcell Technologies) as per the
manufacturer’s instructions. Briefly, CD4+ T cells from
single cell suspensions were first enriched by negative selection using the EasySep™ mouse CD4+ T cell
isolation cocktail from which CD25+ cells were then
positively selected using EasySep™ mouse CD25+ Treg
selection cocktail. The isolated CD4+CD25+ cells were
more than 97% FOXP3+ as determined by flow cytometric analysis. CD4+CD25− Tresps, more than 96%
pure, were collected from naïve non-Tg mice spleens and
used in the proliferation assay after labeling with carboxyfluorescein succinimidyl ester (CFSE) (Catalog no.
C34554, Thermo Fisher Scientific). CD4+CD25+ Tregs
from different experimental groups were serially diluted
in U-bottom 96-well plate to obtain 50, 25, 12.5, and
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6.25 × 103 Tregs in 100 µl of media followed by addition
of 50 × 103 CFSE-labeled Tresps into each well to obtain
Tresp:Treg rations of 1:1, 1:0.5, 1:0.25 and 1:0.125, while
wells with only Tresps served as controls. Mouse T cell
activating CD3/CD28 Dynabeads (Catalog no. 11456D,
Thermo Fisher Scientific) were added to each well at a
bead:Tresp ration of 1:1 to induce Tresp proliferation.
The immunosuppressive function of Tregs to inhibit proliferation of CFSE-stained Tresps was determined after
72 h incubation at 37 °C using flow cytometric analysis
and is reported as Treg-mediated % inhibition.
Transcriptomic and functional and pathway enrichment
analysis

Hippocampal tissue was isolated from mouse brain and
total RNA extracted with the RNAeasy mini kit (Catalog no. 74104, Qiagen). Recovered RNA was reverse
transcribed into cDNA using a RevertAid First Strand
cDNA Synthesis kit (Catalog no. K1622, Thermo Fisher
Scientific). One microgram cDNA was amplified using
primer mix from the RT2-PCR array for Mouse Innate
and Adaptive Immune Responses (Catalog no. 330231,
Qiagen). Quantitative RT-PCR was performed using
Mastercycler Realplex EP (Eppendorf ) and data were
analyzed using RT2 Profiler PCR array web-based
data analysis software (Qiagen). Next, we conducted
functional and pathway enrichment analysis of genes
deregulated in APP/PS1 mice untreated or treated with
Aβ-Teffs compared to non-Tg and APP/PS1 control
mice. GSEA is a method to identify classes of genes or
proteins that over-represented in a large set of genes or
proteins [90]. We conducted GSEA analysis to assess
the enrichment of annotated gene sets in KEGG, Reactome and STRING local network clusters. KEGG pathway enrichment analysis was conducted using DAVID
(http://david.abcc.ncfcrf.gov/) [91], which is an online
tool providing a comprehensive set of functional annotations to understand biological meaning behind large
list of genes. Reactome GSEA analysis was conducted
using ReactomeFIViz (https://reactome.org/tools/react
ome-fiviz) [92], which is a cytoscape app for pathway
and network-based data analysis. STRING local network cluster enrichment analysis was conducted using
STRING (http://string-db.org). KEGG is a database
regarding genomes, biological pathways, diseases,
drugs and chemical substances (http://www.genome/
ad.jp/kegg) [93]. Reactome (http://www.reactome.org)
is an open source, expert-authored, peer-reviewed,
manually curated database of reactions, pathways and
biological processes. STRING (http://string-db.org)
database provides a critical assessment and integration
of protein–protein interaction (PPI), including direct
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(physical) and indirect (functional) associations in a
given organism [94].

Immunohistochemistry

After transcardial perfusion, mouse brains were immediately harvested and divided into two hemispheres.
The left was immediately frozen on dry ice for biochemical analysis and right was immersed in freshly
depolymerized 4% paraformaldehyde in PBS for 48 h
at 4 °C and cryoprotected by immersion in 15% then
30% sucrose for 24 h at 4 °C. Fixed brains were sectioned coronally with a Cryostat (ThermoFisher) with
30-μm-thick sections serially collected and stored
at −80 °C. Immunohistochemistry was performed
using antibodies against pan-Aβ (1:500, rabbit polyclonal, Catalog no. 715800, Thermo Fisher Scientific),
Iba1 (1:1000, rabbit polyclonal, Catalog no. 01919741,
Wako) and doublecortin (Dcx) (1:500, goat polyclonal,
Catalog no. Sc8066, Santa Cruz Biotechnology). For
immunodetection, biotin-conjugated anti-rabbit or
anti-goat IgG secondary antibody was used followed
by a tertiary incubation with Vectastain ABC Elite kit
(Catalog no. PK6100, Vector Laboratories). 1% Thioflavin-S in 50% ethanol was used for counterstaining of
compact amyloid plaque (Catalog no. T1892, Sigma).
For each of the immunohistochemical staining, six sections/slide were collected at eight intervals and were
used for each of the experimental groups. Slides were
masked and coded and Aβ occupied area was calculated using Cavalieri estimator probe (grid spacing
15 μm), while the number of Iba1-reactive microglia
and Dcx-positive (Dcx+) neuroprogenitor cells were
counted using the optical fractionator module of Stereo Investigator system (MBF Bioscience) as described
earlier [9]. Briefly, a high-sensitivity digital camera
(OrcaFlash2.8, Hamamatsu C11440-10C, Hamamatsu,
Japan) interfaced with a Nikon Eclipse 90i microscope
(Nikon, Melville, NY, USA) was used. Within the Stereo Investigator program, the contour in each section
was delineated using a tracing function. While sections
showed tissue shrinkage along the anteroposterior axis,
the extent of shrinkage between different animals was
considered similar. The dimensions for the counting
frame (120 × 100 μm) and the grid size (245 × 240 μm)
were set. The z-plane focus was adjusted at each section for clarity. Cells were quantified by the fractionator with marked positive cells in each counting frame.
Based on the set parameters and marked cell counts,
Stereo Investigator computed cell population estimates
for comparison between groups.
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Western blot analysis

Brain cortical tissues were homogenized using lysis
buffer containing 50 mM Tris–HCl (pH 8.0), 150 mM
NaCl, 50 mM EDTA, 1% Triton X-100, and a mixture
of protease/phosphatase inhibitor (Catalog no. 89901,
Thermo Fisher Scientific). The lysate was centrifuged at
20,000×g for 20 min at 4 °C, the supernatant collected
and total protein quantified using micro-BCA kit (Catalog no. 23235, Thermo Fisher Scientific). For Western
blots, 80 μg or 20 μg of tissue protein was incubated with
β-mercaptoethanol containing Laemmli buffer at 100 °C
for 5 min, followed by electrophoresis on SDS-polyacrylamide gel and transferred to polyvinylidene fluoride
membrane (Immobilon-P, Catalog no. IPVH00010, Millipore). The membranes were blocked in 5% skim milk/
TBST and incubated with primary antibodies to 22C11
(1:2000, Catalog no. MAB348, Millipore Sigma), 6E10
(1:2000, Catalog no. 803001, BioLegend), arginase 1
(1:300, Catalog no. 93668S, Cell Signaling Technology),
iNOS (1:300, Catalog no. 13120S, Cell Signaling Technology), synaptophysin (1:1000, Catalog no. MAB5258,
Millipore), PSD95 (1:1000, Catalog no. ab18258, Abcam)
and β-actin (1:2000, Catalog no. A3854, Sigma) at 4 °C
overnight, followed by 60 min incubation in 5% skim
milk/TBST with horseradish peroxidase-conjugated
anti-rabbit, mouse, or goat secondary antibodies (1:2000,
Santa Cruz Biotechnology). Immunoreactive bands were
detected using SuperSignal West Pico or Femto Chemiluminescent substrate, and images were captured using an
iBlot750 Imager (Thermo Fisher Scientific). Immunoblots
were quantified using ImageJ software (NIH) relative to
β-actin expression.
Aβ detection by ELISA

Mouse cortical tissues were homogenized in 50 mM
Tris–HCl (pH 7.6) containing 150 mM NaCl and a protease/phosphatase inhibitor mixture. The homogenate
was centrifuged at 20,000×g for 20 min at 4 °C and the
supernatant was analyzed for human Aβ1–40 and Aβ1–42
by ELISA (Catalog nos. KHB3482 and KHB3442, Thermo
Fisher Scientific) according to the manufacturer’s
instructions.
Statistical analysis

All data were normally distributed and presented as
mean values ± standard errors of the mean (SEM).
Comparisons of means between groups were analyzed
by one-way ANOVA or two-way repeated measures
ANOVA followed by Newman–Keuls post hoc test
using GraphPad Prizm software version 8.0 (GraphPad Software, San Diego, CA). A value of p ≤ 0.05 was
regarded as a significant difference.
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